What are the adverse effects of roflumilast and tofacitinib when used to treat psoriasis?

Adverse Effects of Roflumilast and Tofacitinib for Psoriasis

Tofacitinib carries significant risks of infection (particularly herpes zoster) and cytopenias, while roflumilast is primarily associated with gastrointestinal symptoms, weight loss, and psychiatric effects including suicidality.

Tofacitinib Adverse Effects

Infections and Immunosuppression

The most clinically significant adverse effect of tofacitinib is herpes zoster infection, which occurs at substantially higher rates than placebo 1. This risk is dose-dependent, with the 10 mg twice daily dose carrying higher infection risk than 5 mg twice daily 1. Zoster vaccination (Shingrix) should be administered before initiating therapy 1.

Hematologic Toxicity

Tofacitinib causes dose-dependent cytopenias 1:

• Do not initiate if lymphocyte count <500 cells/mm³, ANC <1000 cells/mm³, or hemoglobin <9 g/dL
• Discontinue temporarily if lymphocytes or ANC drop below 500 cells/mm³ (confirmed on repeat testing)
• Hold therapy if hemoglobin decreases ≥2 g/dL or falls below 8.0 g/dL

Dose-Related Considerations

The 10 mg twice daily dose demonstrates superior efficacy but carries higher risks of infection and cytopenia compared to 5 mg twice daily 1. Recent evidence from rheumatoid arthritis trials has identified increased risks of venous thromboembolism and pulmonary embolism with the 10 mg dose 2.

Other Adverse Effects

• Upper respiratory tract infections and nasopharyngitis (though meta-analysis showed non-significant differences from placebo) 3, 4
• Serious adverse events occur at low rates comparable to placebo 1, 3
• Should be avoided during active serious infections 1

Special Populations

• Pregnancy: Use only if potential benefit justifies fetal risk 1
• Hepatic impairment: Reduce to 5 mg once daily in moderate/severe impairment; avoid in severe hepatic dysfunction 1
• Renal impairment: Reduce to 5 mg once daily 1

Roflumilast Adverse Effects

Gastrointestinal Effects

Diarrhea is the most common adverse effect, occurring in 9.5% of roflumilast-treated patients versus 2.7% with placebo, and is the leading cause of discontinuation (2.4%) 5. Other GI effects include:

• Nausea (4.7% vs 1.4% placebo) 5
• Abdominal pain, dyspepsia, gastritis, vomiting (1-2% incidence) 5

Weight Loss

Clinically significant weight loss occurs frequently: 7.5% of patients experience weight loss as an adverse event 5. In prospective assessments:

• 20% experience moderate weight loss (5-10% body weight) vs 7% with placebo
• 7% experience severe weight loss (>10% body weight) vs 2% with placebo 5

Monitor weight regularly and consider discontinuation if unexplained or clinically significant weight loss occurs 5. Real-world data confirms mean weight reduction of 6 kg ± 4.3 in 53.4% of patients 6.

Psychiatric Effects

Roflumilast carries a boxed warning for psychiatric events including suicidality 5. Common psychiatric adverse effects include:

• Insomnia (2.4% vs 1.0% placebo)
• Anxiety and depression (1-2% incidence)
• Patients, caregivers, and families must be counseled to monitor for emergence or worsening of insomnia, anxiety, depression, or suicidal thoughts 5

Other Adverse Effects

• Headache (4.4% vs 2.1% placebo)
• Dizziness (2.1% vs 1.1% placebo)
• Decreased appetite (2.1% vs 0.4% placebo)
• Back pain (3.2% vs 2.2% placebo) 5

Serious Adverse Events

Serious adverse events occurring more frequently with roflumilast include diarrhea, atrial fibrillation, acute pancreatitis, and acute renal failure 5. However, overall rates remain low.

Topical Formulations

Topical roflumilast (0.3% cream and foam) demonstrates excellent tolerability with minimal systemic absorption 7, 8. Treatment-emergent adverse events are comparable to vehicle (25-26% vs 18-24%) with no serious adverse events in most trials 7. The topical route substantially reduces systemic exposure and associated risks compared to oral formulation 9.

Key Clinical Pitfalls

Tofacitinib

• Not FDA-approved for psoriasis (off-label use) 1
• Cannot be combined with other potent immunosuppressants (azathioprine, cyclosporine) or biologics 1
• Live vaccines are contraindicated 1
• Requires dose adjustment with strong CYP3A4 inhibitors 1

Roflumilast

• Strong CYP450 inducers (rifampicin, phenobarbital, carbamazepine, phenytoin) reduce efficacy and are not recommended 5
• CYP3A4/CYP1A2 inhibitors may increase exposure and adverse effects 5
• The oral formulation safety data should not be extrapolated to topical formulations due to dramatically different pharmacokinetic profiles 9